As of Sep 30
| -0.0045 / -2.10%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 2.50, with a high estimate of 3.00 and a low estimate of 2.00. The median estimate represents a +1,090.48% increase from the last price of 0.21.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.